← The Wire
KPTINasdaq
Karyopharm Therapeutics Inc.
Pharmaceutical Preparations · DE · CIK 1503802
Develops and commercializes novel cancer therapies targeting nuclear export for treating cancer and other diseases
red 8-K · 90d
$215M
Market cap
$10.09
Last close
-1.2%
1D
+12.1%
5D
497K
Volume
Price · last 39 sessions+8.4%
May 4L $7.14 · H $10.21Jun 29
284
Total filings
May 28, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteMay 28, 202610-Q10-QMay 14, 20268-KResults of OperationsMay 14, 2026DEF 14ADEF 14AApr 13, 20268-KCompany UpdateMar 27, 20268-KMaterial Agreement · Equity IssuanceMar 24, 20268-KMaterial Agreement · Company UpdateMar 3, 20268-KShareholder VoteFeb 19, 202610-K10-KFeb 13, 20268-KResults of OperationsFeb 12, 20268-KResults of Operations · Company UpdateJan 12, 2026DEF 14ADEF 14AJan 9, 202610-Q10-QNov 3, 20258-KResults of OperationsNov 3, 20258-KMaterial Agreement · New Debt / ObligationOct 14, 20258-KExecutive Change · Material AgreementOct 8, 20258-KExecutive ChangeSep 11, 202510-Q10-QAug 11, 20258-KResults of OperationsAug 11, 20258-KReg FD DisclosureJul 11, 20258-KExecutive Change · Shareholder VoteMay 29, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 2025DEFA14ADEFA14AApr 14, 2025DEF 14ADEF 14AApr 14, 20258-KSecurity-Holder Rights · Bylaw AmendmentFeb 24, 202510-K10-KFeb 19, 20258-KResults of OperationsFeb 19, 20258-KExecutive ChangeJan 31, 20258-KShareholder VoteJan 30, 20258-KResults of OperationsJan 13, 20258-KExecutive ChangeJan 2, 2025DEF 14ADEF 14ADec 16, 20248-KReg FD DisclosureDec 3, 20248-KExecutive ChangeNov 20, 20248-KMaterial AgreementNov 8, 202410-Q10-QNov 5, 20248-KResults of OperationsNov 5, 20248-KReg FD Disclosure · Company UpdateOct 31, 2024SC 13GKARYOPHARM THERAPEUTICS INC.Oct 25, 20248-KDelisting NoticeSep 17, 20248-KExecutive ChangeAug 29, 202410-Q10-QAug 6, 20248-KResults of OperationsAug 6, 20248-KExecutive Change · Shareholder VoteMay 31, 2024SC 13GSC 13GMay 23, 20248-KCompany UpdateMay 14, 202410-Q10-QMay 8, 20248-KMaterial Agreement · New Debt / ObligationMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 19, 2024DEF 14ADEF 14AApr 19, 202410-K10-KFeb 29, 20248-KResults of OperationsFeb 29, 20248-KCompany UpdateFeb 20, 2024SC 13GSCHEDULE 13GFeb 13, 20248-KResults of OperationsJan 8, 20248-KDelisting NoticeDec 12, 20238-KExecutive ChangeDec 8, 202310-Q10-QNov 2, 20238-KResults of OperationsNov 2, 20238-KExecutive ChangeSep 1, 202310-Q10-QAug 2, 20238-KResults of OperationsAug 2, 20238-KExecutive Change · Shareholder VoteMay 25, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 4, 2023DEFA14ADEFA14AApr 11, 2023DEF 14ADEF 14AApr 11, 20238-KReg FD DisclosureMar 10, 202310-K10-KFeb 17, 20238-KExecutive ChangeFeb 15, 20238-KResults of OperationsFeb 15, 2023SC 13GSC 13GFeb 10, 2023SC 13GSC 13GJan 20, 20238-KResults of OperationsJan 9, 20238-KCompany UpdateDec 14, 2022SC 13GSC 13GDec 8, 20228-KMaterial Agreement · Equity IssuanceDec 5, 20228-KBylaw AmendmentDec 2, 2022
Insider Activity
In the 90 days to Mar 2, 2026: 7 sold $309K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Paulson Richard A.President and CEO | Sell | 12,361 | $9.41 | $116K |
| Mar 2, 2026 | Poulton StuartEVP, Chief Development Officer | Sell | 5,101 | $9.41 | $48K |
| Mar 2, 2026 | Rangwala ReshmaEVP & Chief Medical Officer | Sell | 5,066 | $9.41 | $48K |
| Mar 2, 2026 | Cheng Sohanya RoshanEVP & Chief Commercial Officer | Sell | 4,604 | $9.41 | $43K |
| Mar 2, 2026 | Mano MichaelEVP, CLO&Secretary | Sell | 3,526 | $9.41 | $33K |
| Mar 2, 2026 | Abate KristinChief Accounting Officer | Sell | 559 | $9.41 | $5K |
| Feb 17, 2026 | Poulton StuartEVP, Chief Development Officer | Sell | 378 | $8.63 | $3K |
| Feb 3, 2026 | Macomber LoriEVP, CFO & Treasurer | Sell | 1,626 | $6.30 | $10K |
| Jan 28, 2026 | Abate KristinChief Accounting Officer | Sell | 50 | $7.03 | $352 |
| Jan 21, 2026 | Abate KristinChief Accounting Officer | Sell | 265 | $5.96 | $2K |
| Oct 1, 2025 | Abate KristinChief Accounting Officer | Sell | 362 | $6.30 | $2K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance